ERBB2 and lung adenocarcinoma: In contrast to lung adenocarcinoma, in which HER2 amplification and BRAFV600E mutation appear to be mutually exclusive events [34], here we found that all HER2+ fPTC bore the BRAFV600E mutation, although not all BRAFV600E-positive nodules had HER2 amplification.